Journal of substance use and addiction treatment最新文献

{"title":"C2: editorial board","authors":"","doi":"10.1016/S2949-8759(25)00106-7","DOIUrl":"10.1016/S2949-8759(25)00106-7","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"174 ","pages":"Article 209727"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicaid health home design and buprenorphine receipt, 2009–2020","authors":"Christina M. Andrews ,&nbsp;Theodoros Giannouchos ,&nbsp;Angela Rogers ,&nbsp;Melissa A. Westlake","doi":"10.1016/j.josat.2025.209738","DOIUrl":"10.1016/j.josat.2025.209738","url":null,"abstract":"<div><h3>Introduction</h3><div>In the midst of an escalating opioid epidemic, innovative models of care are critical to expand access to opioid use disorder treatment. The Medicaid health home program, which costs the nation $1 billion annually, is intended to improve identification and treatment for enrollees with complex chronic conditions, including opioid use disorder. In this study, we assess the association of state-level Medicaid health home policies related to substance use disorder screening and health home eligibility with trends in prescriptions for buprenorphine, a medication that dramatically reduces risk of opioid-related overdose and mortality.</div></div><div><h3>Methods</h3><div>We use Medicaid data on buprenorphine prescriptions from 2009 to 2020 and a difference in differences methodology accounting for variation in treatment timing. Our treatment groups are states that require health homes to screen for substance use disorder and states that had at least one health home that has substance use disorder as a qualifying condition.</div></div><div><h3>Results</h3><div>We find no significant difference in rates of buprenorphine prescriptions filled among states that require screening for substance use disorder and those that do not. We also do not find significant differences in buprenorphine prescriptions between states that designate substance use disorder as a qualifying condition for health home participation and those that do not.</div></div><div><h3>Conclusion</h3><div>Health home policies intended to reach opioid use disorder patients are not increasing buprenorphine receipt, which is one key measure of opioid use disorder treatment. State Medicaid programs should assess strategies to enhance health home performance in facilitating access opioid use disorder treatment.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209738"},"PeriodicalIF":0.0,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of substance use disorder and mental health disorder treatment facilities with perinatal programs","authors":"Brooke N. Lombardi ,&nbsp;Anna B. Parisi ,&nbsp;Helen Newton ,&nbsp;Brianna M. Lombardi","doi":"10.1016/j.josat.2025.209722","DOIUrl":"10.1016/j.josat.2025.209722","url":null,"abstract":"<div><h3>Background</h3><div>Substance use disorders (SUD) and mental health disorders (MHD) are major health concerns during the perinatal period (conception to one year postpartum). However, many individuals with perinatal SUD or MHD do not receive adequate treatment, and most treatment facilities do not offer services tailored to this population's unique needs. This study examines the proportion of treatment facilities in the United States (US) providing perinatal services, as well as facility- and state-level factors associated with offering such services.</div></div><div><h3>Methods</h3><div>Data were drawn from the 2022 National Substance Use and Mental Health Services Survey, an annual cross-sectional survey of all known public and private SUD and MHD treatment facilities in the US. The sample consisted of 6995 facilities providing SUD treatment (SUD-only) and 9134 facilities offering combined SUD and MHD treatment. Descriptive statistics, bivariate analyses, and multilevel logistic regression models examined treatment facility characteristics and the impact of facility- and state-level factors on the likelihood of offering perinatal services.</div></div><div><h3>Results</h3><div>Only 32.7% of SUD-only treatment facilities and 31.1% of combined SUD/MHD treatment facilities offered perinatal programs. More than half of these treatment facilities provided services critical to the perinatal population, including transportation assistance, social service support, trauma-informed therapy, and telehealth. Payment type (i.e., Medicaid acceptance, offer of free or low-cost treatment), for-profit treatment facility ownership, and receipt of state and federal grant funding were associated with a significantly increased likelihood of the treatment facility providing perinatal services.</div></div><div><h3>Conclusions</h3><div>Findings indicate there is a pressing need for SUD and MHD treatment facilities to expand their services to include care for individuals in the perinatal period, as well as increase the availability of essential services (e.g., integrated primary care) and ancillary services (e.g., childcare). Further research is needed to understand at which timepoint(s) facilities provide treatment (i.e., pregnancy and/or the postpartum period) and which types of essential and ancillary services are most beneficial during the perinatal period.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209722"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"I will always be a mother. Now, I am an advocate","authors":"Amy Bogert,&nbsp;Jack J. Lu","doi":"10.1016/j.josat.2025.209724","DOIUrl":"10.1016/j.josat.2025.209724","url":null,"abstract":"<div><h3>Background</h3><div>Mason Bogert lived a brilliant life. His struggle with co-occurring substance use and mental health conditions culminated into lifelong paths of recovery for him and his mother, Amy Bogert.</div></div><div><h3>Methods</h3><div>Amy shares her lived experience as Mason's parent and caregiver alongside a national context of youth co-occurring disorder prevalence and resulting effects. Best practice and evidence-based strategies are identified, such as family involvement, integrated treatment, and youth-empowered community level prevention.</div></div><div><h3>Results</h3><div>Presently, Amy focuses on advocacy for youth co-occurring and substance use care across a continuum of prevention, integrated treatment, and recovery services. Amy's deepest hope is that youth, like Mason, and their loved ones experience less isolation and more opportunities in preventing the progression of co-occurring and substance use disorders.</div></div><div><h3>Conclusions</h3><div>Evidence-based youth co-occurring prevention and integrated treatment services are essential for youth and their families.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209724"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing unmet need for substance use disorder treatment among youth in the legal system (YLS): Costs of structured implementation interventions with juvenile justice agencies in seven states","authors":"Kathryn E. McCollister ,&nbsp;Diana Bowser ,&nbsp;Jenny E. Becan ,&nbsp;Danica K. Knight ,&nbsp;Steven Belenko ,&nbsp;Angela A. Robertson ,&nbsp;Michael L. Dennis","doi":"10.1016/j.josat.2025.209721","DOIUrl":"10.1016/j.josat.2025.209721","url":null,"abstract":"<div><h3>Introduction</h3><div>Implementation of integrated strategies for improving access to behavioral health services for youth in the legal system requires evidence of the costs of changing existing practices, and stakeholders need to be aware of what types of investments (e.g., personnel, data systems) lead to more efficient implementation and better outcomes.</div></div><div><h3>Methods</h3><div>A cost analysis was conducted alongside the Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS), a research cooperative comprising 34 community supervision agencies in seven states that were randomly assigned to Core or Core+Enhanced implementation interventions. Both were focused on improving screening, referral, and linkage to behavioral health services for youth with substance use disorders (SUD). Cost data were collected prospectively across all implementation phases.</div></div><div><h3>Results</h3><div>During Baseline, the average cost was $11,083 per site (range: $1104 to $19,399). Enhanced sites had relatively higher baseline costs ($13,176 vs. $9222 in the Core sites). During the Experiment phase, Enhanced sites continued to incur higher implementation costs relative to the Core sites, but these costs steadily declined and ultimately converged with Core sites as they entered the sustainment phase.</div></div><div><h3>Conclusions</h3><div>Enhanced sites had higher implementation costs; but both Enhanced and Core sites showed similar trends in decreasing costs across the Experiment period. These decreasing costs reflected both fewer meetings and lower participation over time. In a funding climate where available resources are already scarce, access to cost data can help agencies prepare to implement and sustain new practices.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"176 ","pages":"Article 209721"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription opioid spillovers: Retail pharmacy level analysis","authors":"Collin D. Hodges ,&nbsp;Shishir Shakya","doi":"10.1016/j.josat.2025.209725","DOIUrl":"10.1016/j.josat.2025.209725","url":null,"abstract":"<div><h3>Introduction</h3><div>Prescription drug monitoring programs (PDMPs) are state-level initiatives designed to curb opioid misuse. This study investigates the impact of “must-access” PDMP mandates–which require healthcare providers to consult the PDMP database before prescribing opioids–on retail opioid sales in the United States. It also examines potential spillover effects on neighboring states without such mandates.</div></div><div><h3>Methods</h3><div>A generalized difference-in-differences analysis assessed the effect of PDMP mandate implementation on retail opioid sales from 2006 to 2014. The study utilized geocoded data encompassing the universe of individual retail pharmacies across the United States. This methodology allowed for the comparison of opioid sales trends in states implementing “must-access” PDMP policies with those that did not, both before and after policy enactment. The geocoded pharmacy data facilitated the analysis of spatial spillover effects on neighboring states.</div></div><div><h3>Results</h3><div>This study provides evidence that the implementation of “must-access” PDMP mandates was associated with a decrease in retail opioid sales within the enacting states. Furthermore, results suggest the presence of spillover effects in pharmacies in neighboring states without such policies. This suggests that PDMP mandates in one state can influence opioid dispensing patterns in adjacent states.</div></div><div><h3>Conclusions</h3><div>State-level “must-access” PDMP mandates effectively reduce retail opioid sales within enacting states. However, observed spillover effects highlight the potential for state-level variation in opioid policy to generate unintended consequences. These findings highlight the potential for cross-state coordination in opioid policy to improve outcomes.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209725"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144184443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-stop shopping for recovery? A systematic review of the evidence on U.S. recovery community centers","authors":"John F. Kelly,&nbsp;Jenny B. O'Connor,&nbsp;Morgan R. Klein,&nbsp;Lauren A. Hoffman,&nbsp;David Eddie,&nbsp;Corrie L. Vilsaint,&nbsp;Brandon G. Bergman,&nbsp;Emily A. Hennessy","doi":"10.1016/j.josat.2025.209723","DOIUrl":"10.1016/j.josat.2025.209723","url":null,"abstract":"<div><h3>Background</h3><div>Increased recognition of the need for community-based substance use disorder (SUD) recovery support services (RSS) to complement and extend clinical care efforts has led to growth in a variety of RSS including recovery community centers (RCCs). Given increased national focus on expanding RCC research, this systematic review examined published research on RCCs.</div></div><div><h3>Method</h3><div>We searched five publicly available empirical databases to retrieve existing studies on the effects of RCC participation through May 2024. Standardized summarization and quality assessment tools were utilized to provide systematic reporting and ratings of study quality.</div></div><div><h3>Results</h3><div>Seven studies (participant Ns range = 78 to 3459) were included, none of which were randomized/non-randomized comparative effectiveness designs; four were single-group prospective/retrospective and three, cross-sectional. The longest follow-up duration was limited to 6-months. Participants were mostly white, male, with high clinical pathology, low socio-economic status, and low recovery capital; primary substance was inconsistently reported, but mostly opioids or alcohol. RCC participation duration and intensity were positively associated with improvements in substance use, recovery capital, and psychosocial functioning. Major limitations pertained to inadequate description of samples, no “intent-to-treat” analyses, lack of inferential analyses, and atheoretical delineations of tested models and variables.</div></div><div><h3>Conclusions</h3><div>Despite national growth of RCCs, the quantity and quality of existing evidence is limited. Where reported, participation appears to be correlated with reductions in substance use and improved well-being. The limited evidence suggests RCCs may serve as a distinct, visible community access point for individuals with high psychopathology and low recovery capital to access support and resources. Given the disparity between the observed growth and promising preliminary results of RCCs and lack of rigorous evaluation, this review highlights a compelling need for further research investment to provide better estimates of the potential clinical and public health utility of RCCs in the RSS landscape.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209723"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144184444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC (update)","authors":"","doi":"10.1016/S2949-8759(25)00093-1","DOIUrl":"10.1016/S2949-8759(25)00093-1","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"173 ","pages":"Article 209714"},"PeriodicalIF":0.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C2: editorial board","authors":"","doi":"10.1016/S2949-8759(25)00092-X","DOIUrl":"10.1016/S2949-8759(25)00092-X","url":null,"abstract":"","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"173 ","pages":"Article 209713"},"PeriodicalIF":0.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143932128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Counseling as a complement to buprenorphine treatment for opioid use disorder: A retrospective observational study of patient outcomes","authors":"Tianjie Zhu ,&nbsp;Md. Noor-E-Alam ,&nbsp;Md Mahmudul Hasan ,&nbsp;Leonard D. Young ,&nbsp;Gary J. Young","doi":"10.1016/j.josat.2025.209719","DOIUrl":"10.1016/j.josat.2025.209719","url":null,"abstract":"<div><h3>Introduction</h3><div>This study investigated the clinical benefit of counseling as a complement to buprenorphine treatment for opioid use disorder (OUD). The research addresses a critical gap in understanding whether counseling, when received concurrently with buprenorphine, can enhance patient outcomes.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using data from the Massachusetts Department of Public Health's Public Health Data Warehouse (PHD). The study included patients who initiated buprenorphine treatment between January 2015 and December 2019. Investigators measured outcomes including medication adherence, treatment discontinuation, and opioid-related overdose over a 12-month period. We evaluated the effectiveness of counseling based on whether patients attended a minimum of three sessions in the first three months of buprenorphine treatment. We employed multivariate logistic regression and propensity score matching to analyze the data.</div></div><div><h3>Results</h3><div>The study sample comprised 32,688 patients with 8871 (27 %) receiving counseling concomitantly with buprenorphine. Results from the regression analyses showed that counseling was associated with 17 % lower likelihood of poor medication continuity (OR = 0.83, 95 % CI = 0.78–0.87) and 21 % lower likelihood of treatment discontinuation (OR = 0.79, 95 % CI = 0.75–0.83). Counseling was not associated with the odds of opioid-related overdose. Additional results from sensitivity analyses pointed to a dose-response relationship for counseling within the parameters studied.</div></div><div><h3>Conclusions</h3><div>Findings suggest that counseling, when combined with buprenorphine treatment for OUD is associated with better patient outcomes in terms of medication continuity and treatment retention. However, the impact of counseling on opioid-related overdose risk was inconclusive, highlighting the need for further research to understand its role in overdose prevention.</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"175 ","pages":"Article 209719"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}